Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents

Hamano, Itsuto; Yoneyama, T.; Tobisawa, Yuki; Sato, Osamu; Matsumoto, Teppei; Yamamoto, Hayato; Imai, Atsushi; Yoneyama, Takahiro; Hashimoto, Yasuhiro; Koie, Takuya; Οhyama, Chikara

doi:10.1186/s40064-016-3610-6

Cited by 3 publications

(1 citation statement)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings were confirmed for TRUS biopsies by Hamano and colleagues in a large retrospective study. 42 Heparin bridging for VKA users significantly increases the risk of bleeding compared to discontinuation. Again, the authors emphasized the lack of clear data and recommendations.…”

Section: Discussionmentioning

confidence: 99%

New oral anti-coagulation drugs and prostate biopsy: a call for guidelines

Coscarella

Motte

Dalati

et al. 2018

Therapeutic Advances in Urology

View full text Add to dashboard Cite

Background:Prostate biopsy is a rather frequent procedure, mostly performed in outpatient settings. Bleeding complications following this procedure require precise and delicate management of pre-, peri- and post-procedure anti-coagulation treatments. New oral anti-coagulation drugs (NOACs) are increasingly used. However, the management of such treatments is feared and not yet well known to urologists. A protocol for prostate biopsy management of NOACs seems mandatory.Materials and methods:A review of the literature, using Pubmed and Cochrane databases, together with analysis of several medical associations’ recommendations in urology, anaesthesiology, cardiology, oncology and drug safety agency, was performed.Results:There are no recommendations about NOAC management for prostate biopsy available from scientific societies. There is also a lack of specific urological studies. However, several panels of expert recommendations could be helpful in establishing standardized protocols adapted from surgery to prostate biopsy. With the growing use of NOACs, recommendations have shifted to continue anti-coagulant treatment without bridging NOACs for low bleeding risk procedures such as prostate biopsy, in carefully selected groups of patients.Conclusion:Extensive indications coupled with the ease of use of NOACs contribute significantly to the widespread replacement of traditional vitamin K antagonist. Knowing that heparin bridging leads to more bleeding, and in the pursuit of more autonomy and safety, urologists should be able to propose dedicated anti-coagulant management using NOACs adapted to carefully selected patients before the prostate biopsy procedure. Further studies and guidelines specific to the concept of non-bridging for anti-coagulant-requiring patients are mandatory for this routine procedure.

show abstract

Section: Discussionmentioning

confidence: 99%

New oral anti-coagulation drugs and prostate biopsy: a call for guidelines

Coscarella

Motte

Dalati

et al. 2018

Therapeutic Advances in Urology

View full text Add to dashboard Cite

show abstract

Impact of the Proportion of Biopsy Positive Core in Predicting Biochemical Recurrence in Patients with Pathological Pt2 and Negative Resection Margin Status after Radical Prostatectomy

Oikawa

Tanaka

Narita

et al. 2020

Pathol. Oncol. Res.

View full text Add to dashboard Cite

Peri‐procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH

Wang

Sanfilippo

Douketis

et al. 2022

Journal of Thrombosis and Haemostasis

View full text Add to dashboard Cite

Patients with cancer have an increased risk of thrombosis requiring anticoagulants and/or antiplatelet agents, and they can also encounter thrombocytopenia due to cancer itself or cancer therapies. They often undergo many procedures such as tissue or bone marrow biopsies, placement of central access lines, diagnostic or therapeutic draining procedures, lumbar puncture, and more. Management of antithrombotic agents or thrombocytopenia around the time of these procedures is highly variable.In this document, the Hemostasis and Malignancy Subcommittee of the International Society on Thrombosis and Haemostasis aims to provide useful practice guidance in the management of antithrombotic agents and thrombocytopenia around the time of common procedures in patients with cancer.

show abstract

Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents

Cited by 3 publications

References 22 publications

New oral anti-coagulation drugs and prostate biopsy: a call for guidelines

New oral anti-coagulation drugs and prostate biopsy: a call for guidelines

Impact of the Proportion of Biopsy Positive Core in Predicting Biochemical Recurrence in Patients with Pathological Pt2 and Negative Resection Margin Status after Radical Prostatectomy

Peri‐procedure management of antithrombotic agents and thrombocytopenia for common procedures in oncology: Guidance from the SSC of the ISTH

Contact Info

Product

Resources

About